New Key Statistics Module, Z-Score and F-Score
AMEX:LCTX Key Ratios
| Market Cap $ M | 175.52 |
| Enterprise Value $ M | 136.62 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 2.58 |
| Price/Sales | 27.33 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 6.00 |
| EPS (TTM) $ | -0.13 |
| Beneish M-Score | -3.09 |
| 10-y EBITDA Growth Rate % | 16.30 |
| 5-y EBITDA Growth Rate % | 13.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -5.34 |
| EV-to-EBITDA | -5.48 |
| PEG | -- |
| Shares Outstanding M | 188.84 |
| Net Margin (%) | -391.00 |
| Operating Margin % | -413.76 |
| Pre-tax Margin (%) | -391.25 |
| Quick Ratio | 2.64 |
| Current Ratio | 2.64 |
| ROA % (ttm) | -22.81 |
| ROE % (ttm) | -35.06 |
| ROIC % (ttm) | -33.59 |
| Dividend Yield % | -- |
| Altman Z-Score | -2.96 |
LCTX Number of Guru Trades
LCTX Volume of Guru Trades
Gurus Latest Trades with AMEX:LCTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
AMEX:LCTX is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Lineage Cell Therapeutics Inc Insider Transactions
No Available Data
News about AMEX:LCTX
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers